Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: The EFFORT study

Journal of Clinical Hypertension

Volumn 15, Issue 7, 2013, Pages 473-479

  Briasoulis, Alexandros ^a   Oliva, Raymond ^a   Kalaitzidis, Rigas ^a   Flynn, Colleen ^a   Lazich, Ivana ^a   Schlaffer, Carrie ^a   Bakris, George ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEMOGLOBIN A1C; LISINOPRIL; LOSARTAN; METOPROLOL SUCCINATE; NEBIVOLOL;

ADULT; AFRICAN AMERICAN; AGED; AORTA PRESSURE; ARTERY COMPLIANCE; ARTICLE; AUGMENTATION INDEX; BRACHIAL ARTERY; BRADYCARDIA; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART RATE; HEMODYNAMIC PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULSE WAVE; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TONOMETRY;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AFRICAN AMERICANS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTA; BENZOPYRANS; BLOOD PRESSURE; COMORBIDITY; DIABETES MELLITUS, TYPE 2; ETHANOLAMINES; FEMALE; HEART RATE; HEMODYNAMICS; HUMANS; HYPERTENSION; LISINOPRIL; LOSARTAN; MALE; METOPROLOL; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84879798282     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12118     Document Type: Article

References (28)

1. Ladage D, Brixius K, Hoyer H, et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006;33:720-724.
2. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511-514.
3. Dessy C, Moniotte S, Ghisdal P, et al. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation. 2004;110:948-954.
4. Garban HJ, Buga GM, Ignarro LJ. Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol. 2004;43:638-644.
5. Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677-684.
6. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251-1257.
7. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795-3801.
8. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605.
9. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10-15.
10. Kocyigit I, Kaya MG, Orscelik O, et al. Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol. 2012;36:11-18.
11. Peralta CA, Norris KC, Li S, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012;172:41-47.
12. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
13. Schram MT, Henry RM, van Dijk RA, et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension. 2004;43:176-181.
14. Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122-1128.
15. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663-667.
16. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236.
17. Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59:893-898.
18. Dhakam Z, McEniery CM, Yasmin, et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006;19:214-219.
19. Manolis AJ, Iraklianou S, Pittaras A, et al. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens. 2005;18:18-22.
20. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens. 2005;23:551-556.
21. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17:118-123.
22. Warmack TS, Estes MA, Heldenbrand S, Franks AM. Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother. 2009;43:2031-2043.
23. Davies J, Carr E, Band M, et al. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? J Renin Angiotensin Aldosterone Syst. 2005;6:151-153.
24. Khan BV. The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function. Ther Adv Cardiovasc Dis. 2011;5:241-273.
25. Akgullu C, Ozdemir B, Yilmaz Y, et al. Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease. Acta Cardiol. 2008;63:467-471.
26. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010;8:638-644.
27. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99:431-436.
28. Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:309-315.